EGFR-mutated NSCLC

Latest news

Tag

Izalontamab Brengitecan Shows Promising Efficacy Over Platinum Chemotherapy in EGFR-Mutated NSCLC Post-Third-Generation EGFR TKI Progression

The PANKU-Lung01 phase 3 trial demonstrates izalontamab brengitecan significantly extends progression-free survival compared to platinum-based chemotherapy in EGFR-mutated advanced non-squamous NSCLC after failure of third-generation EGFR T

Nov 3, 2026

Clinical Updates

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an accep

Sep 8, 2025

Clinical Updates

Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study

Savolitinib plus osimertinib showed clinically meaningful responses in patients with EGFR-mutated advanced NSCLC and high MET overexpression/amplification after progression on first-line osimertinib, offering a new targeted therapy option.

Aug 8, 2025Sign in to read